Hemostemix $HEM presently possesses the entirety of the intellectual property, which involves all the HS 12-01 2nd phase trial data and all the verified information from Hemostemix Israel.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
